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OBJECTIVES The goal of this study was to determine whether right ventricular (RV) ischemia is a
contributory factor in the development of RV dysfunction in patients with primary pulmonary
hypertension (PPH).
BACKGROUND Patients with advanced PPH develop RV dysfunction, characterized by a decreased cardiac
output, increased right atrial pressure (RAP) and/or elevated RV end-diastolic pressure,
which progresses to heart failure and death. The cause of this dysfunction is unknown. Right
ventricular ischemia may play a role in its development.
METHODS From 1992 to 1999, a prospective study involving 23 patients with PPH at the Instituto
Nacional de Cardiologia “Ignacio Chavez” (Mexico City, Mexico) was undertaken. These
patients were evaluated clinically and further studied by echocardiography, right heart
catheterization and stress myocardial scintigraphy using technetium 99m sestamibi.
RESULTS Nine patients of 23 were found to have scintigraphic images consistent with RV ischemia.
Significant correlation was found between RV ischemia obtained through myocardial
perfusion scintigraphy and elevation of RV end-diastolic pressure (p , 0.001), elevation of
RAP (p , 0.037) and a decrease in mixed venous oxygen saturation (p , 0.0001). No other
clinical or hemodynamic variables showed a significant correlation with RV ischemia.
CONCLUSIONS A direct correlation exists between RV ischemia, as determined by myocardial scintigraphy,
and hemodynamic alterations suggestive of RV dysfunction in patients with PPH. (J Am
Coll Cardiol 2001;38:1137–42) © 2001 by the American College of Cardiology
Primary pulmonary hypertension (PPH) is a disease of
unknown etiology and poor prognosis. Platelet (1), endo-
thelial (2) and K1 channel (3) dysfunction, as well as
alterations in the prostaglandin metabolism (4) have been
suggested as probable causes of this disease, but there is still
no consensus on its etiology. Patients with end stage PPH
develop progressive right ventricular (RV) dysfunction,
characterized by a hemodynamic pattern of decreased car-
diac output and increased right atrial pressure (RAP) and/or
RV end-diastolic pressure (RVEDP) (5,6) leading to heart
failure and death. These hemodynamic parameters can be
used to predict the probability of survival after diagnosis
(6,7).
Attempts to explain the cause of RV dysfunction have
yielded at least three hypotheses. First, a genetic predispo-
sition based on angiotensin-converting enzyme isotypes
may play a permissive role in the development of RV
hypertrophy or failure as a result of pulmonary hypertension
(8). Second, excessive adrenergic stimulation, as seen in
heart failure, downregulates beta-adrenergic receptor ex-
pression and may impair RV function (9–13). Third,
myocardial ischemia, a known cause of ventricular dysfunc-
tion, may also be involved in this process.
Myocardial scintigraphy utilizing thallium 201 (201Tl) or
technetium 99m (99mTc) sestamibi is an instrument readily
available for the evaluation of myocardial perfusion. Detec-
tion of RV ischemia using nuclear imaging has recently been
validated (14,15). In the general population, the size and
width of the RV walls limit this technique’s usefulness. In
patients with PPH, chronic exposure to pressure overload
induces RV hypertrophy, increases radiotracer uptake and
enhances its visualization when using myocardial scintigra-
phy (16). This study’s objectives are: 1) to evaluate the
presence of RV ischemia using myocardial scintigraphy in
patients with PPH; and 2) to analyze the association
between ischemia and RV dysfunction in this patient
population.
METHODS
A prospective study starting in September 1992 and ending
in September 1999 in the Cardiopulmonary and Nuclear
Cardiology Departments of the Instituto Nacional de Car-
diologia “Ignacio Chavez” (Mexico City, Mexico) was
undertaken. Twenty-three incident cases of PPH, with a
median age of 23 years, were included. Patients were
Hispanic in origin and predominantly women, with a
female-to-male ratio of 3.6:1. The diagnosis of PPH was
considered for all patients that fulfilled the diagnostic
criteria (5) consisting of: elevation of the mean resting
pulmonary arterial pressure .22 mm Hg, pulmonary cap-
illary wedge pressure within normal limits (when measur-
able) and absence of any concomitant disease known to
cause or be associated with elevation of the mean pulmonary
arterial pressure. These patients were scrutinized with a
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diagnostic evaluation, which included a clinical history and
physical examination, chest X-ray, 12-lead electrocardio-
gram with leads v3r and v4r, complete blood count, eryth-
rocyte sedimentation rate, immunological workup, pulmo-
nary function tests, ventilation/perfusion lung scan, right
heart catheterization, myocardial scintigraphy and two-
dimensional echocardiography. Patients over 40 years of age
underwent coronary angiography to rule out the presence of
epicardial coronary artery disease. All the procedures were
approved by the ethics committee at our institution and
were practiced after receiving their written consent.
Patients were excluded if they presented: an abnormal
coronary angiography; congenital, acquired valvular or myo-
cardial disease; chronic thromboembolic pulmonary hyper-
tension; obstructive or restrictive lung disease; parasitic
involvement of the lungs; cirrhosis; collagen vascular dis-
ease; or antiphospholipid syndrome.
Echocardiography. Patients underwent transthoracic
echocardiographic evaluation using Hewlett Packard Sonos
1000, 1500 and 5500 machines and 3.5 MHz transducers to
obtain conventional measurements of left atrial, aortic and
left ventricular (LV) dimensions; atrial and ventricular
septum integrity; and LV ejection fraction. Right ventricu-
lar diastolic free wall width, diastolic RV dimensions and
RV wall motion were measured and graded (17). Doppler
interrogation was used to quantify the pulmonary arterial
pressure determined by the grade of tricuspid insufficiency
and transtricuspid pressure gradient (18). If the integrity of
the interventricular or interauricular septum was in doubt,
the study was complemented with a contrast transesopha-
geal echocardiogram.
Hemodynamic measurements. The RAP, RV and pulmo-
nary variables were measured by right heart catheterization
(19,20). Brachial artery cannulation was performed for
blood sampling and systemic pressure measurement. Car-
diac output was calculated in triplicate by thermodilution.
The data was interpreted independent of knowledge of the
myocardial scintigraphy and echocardiographic findings.
Nuclear cardiology. Myocardial scintigraphy was per-
formed on each patient. Single photon emission computed
tomography (SPECT) or gated SPECT (GSPECT) myo-
cardial perfusion imaging studies were obtained from 1992
to 1996 and 1997 to 1999, respectively. Stress was induced
by a symptom-limited exercise test using the multistage
modified Bruce (21) or Balke (22) protocol aimed to achieve
$85% of the maximal predicted heart rate. Exercise end
points included physical exhaustion, severe angina, sus-
tained ventricular tachycardia, hemodynamically significant
supraventricular arrhythmias or significant exertional hypo-
tension. In patients with decreased exertional capacity, a
0.5 mg/kg intravenous dipyridamole 5 min infusion was
used to induce pharmacologic stress.
SPECT. Single photon emission computed tomography
images using 99mTc sestamibi were gathered in 23 patients
(including 13 GSPECT) with a Siemens Orbiter 2000
gamma camera and an Icon A/P processing system utilizing
the Cedars-Sinai Quantitative Gated SPECT program
(23). A one-day protocol with 99mTc sestamibi was used
(24). Single photon emission computed tomography acqui-
sitions employed a large field gamma camera view and a
low-energy, high-resolution collimator to obtain 32 projec-
tions at 30 s per projection over a semicircular arc.
Right ventricular SPECT was independently studied
after a modification of De Puey’s technique (14,25) and
included post-stress GSPECT imaging (23). A classical
short-axis reconstruction of the LV was performed in each
patient. From this view, the RV was isolated and manually
delineated to define the lateral, anterior and inferior RV wall
at the middle and basal third of the short axis (Fig. 1).
When subdiaphragmatic radiotracer activity did not permit
adequate definition of the inferior wall, the patient was not
included in the analysis. The LV, left hemithorax and
abdominal background activity were masked, and the radio-
isotope counts were maximized over the RV walls at rest and
during stress.
Right ventricular perfusion was scored by the consensus
of three observers (D.B., A.G., E.S.) using a 5 point scoring
system: 0 5 normal uptake, 15 equivocal, 2 5 moderate
reduction of radioisotope uptake, 3 5 severe reduction of
radioisotope uptake, 4 5 absence of detectable radiotracer
in a segment. The comparison of the RV perfusion images
at rest and during stress was the basis of the diagnosis of
ischemia, infarct and reverse-reversibility using the same
criteria as images of the LV. No attenuation program was
used. Patients were defined as having RV ischemia if all
three observers concurred on the visualization of perfusion
defects. The physicians interpreting the scintigraphy did not
have access to the results of the right heart catheterization,
echocardiographic findings and medical history.
To evaluate the RV size confidently, an RV size index
was developed by measuring the maximal RV diameter 3
100/maximal heart diameter (Fig. 1). The dimensions were
taken from the short-axis view of the scintigraphy. It was
scored as the following: “0” (size index ,10%); mild
dilation, “1” (size index 11% to 20%); moderate dilation, “2”
(size index 21% to 30%); severe dilation, “3” (size index
.30%).
Abbreviations and Acronyms
CI 5 confidence interval
GSPECT 5 gated single photon emission computed
tomography
LV 5 left ventricle/left ventricular
NYHA 5 New York Heart Association
PPH 5 primary pulmonary hypertension
RAP 5 right atrial pressure
RV 5 right ventricle/right ventricular
RVEDP 5 right ventricular end-diastolic pressure
SPECT 5 single photon emission computed
tomography
99mTc 5 technetium 99m
201Tl 5 thallium 201
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Statistical analysis. The data were analyzed with descrip-
tive statistics (median [50th percentile], 25th and 75th
percentiles) and univariate analysis using Mann-Whitney U
test because the sample did not have a normal distribution.
Dichotomous nominal variables were analyzed with chi-
square test. Statistical analysis was performed using the
computer packages SPSS (SPSS, Inc., Chicago, Illinois).
All clinical and hemodynamic variables were considered to
be statistically significant with a p , 0.05.
Intra-observer variability was measured by the Kappa test.
Interpreters re-evaluated the SPECT images three days
after the original reading, unaware of their initial impres-
sion, obtaining a kappa of 0.95. Inter-observer variability
was calculated as: 1 versus 2 5 0.90, 2 versus 3 5 0.80 and
1 versus 3 5 0.84.
RESULTS
Cardiac perfusion imaging. All patients had a myocardial
scintigraphy with 99mTc sestamibi. All of the patients had
SPECT, and GSPECT was used to evaluate 13 of them.
Stress was induced by exercise in four patients and by
dipyridamole in 19 patients. The RV walls of all patients
were adequately delineated. Patients were characterized into
two groups based on the results of the scans. Group 1
(nonischemic) consisted of 14 patients, and group 2 (isch-
emic) consisted of nine patients (Fig. 1 and 2).
In group 2, dipyridamole was used to cause stress in all
the patients. Ischemia was found in the lateral (four pa-
tients), inferior (seven patients) and anterior (two patients)
RV walls. Simultaneous ischemia in two RV walls was
evident in four patients. No fixed perfusion defects were
detected in our patients.
Findings common to both groups included leftward
septal deviation, a relatively small LV and moderate-to-
severe RV dilation (size index from 23% to 69%). Right
ventricular hypertrophy was evident in all of the patients,
regardless of the presence of ischemia. Hypokinesis of the
RV walls was found in all patients in group 2 and two of the
patients in group 1.
Correlations between RV ischemia and other clinical
parameters. The most common presenting symptom was
dyspnea (93% vs. 95% in groups 1 and 2, respectively),
followed by the presence of palpitations (71% vs. 78%).
Forty-three percent of the patients complained of angina or
its equivalent (29% vs. 67% in groups 1 and 2, respectively
[p 5 0.07]). Clinical signs of right heart failure (edema,
hepatomegaly and elevated jugular pressure) were present in
both groups. There was a greater tendency for patients with
New York Heart Association (NYHA) class III/IV to be
found in group 2 (21.4% vs. 44.4% [p 5 0.23]).
None of the changes noted in the electrocardiogram or
pulmonary function tests correlated with the presence or
absence of RV ischemia.
Hemodynamic parameters. The right side cardiac cathe-
terization results are presented in Table 1. Median RAP
(4.8 mm Hg vs. 8 mm Hg [p , 0.037]) and RVEDP
(6.95 mm Hg vs. 12.6 mm Hg [p , 0.001]) in group 2 were
elevated when compared with group 1. Patients with RV
ischemia had lower mixed venous oxygen saturation when
compared with those obtained in the nonischemic group
(65% vs. 48% [p 5 0.001]). No significant differences were
found while analyzing the systolic RV pressure, cardiac
index, mean pulmonary arterial pressure and arterial O2
saturation.
Echocardiography. There were no differences noted be-
tween the RV free wall widths and RV diastolic diameters
between the groups (Table 1).
DISCUSSION
The natural history of PPH is characterized by a relatively
silent progression until RV dysfunction develops. This is
clinically manifested by dyspnea of increasing severity and
other physiologic effects resulting from low cardiac output
such as syncope and seizures (6,7,26). From this stage on,
Figure 1. (A) Schematic representation of the heart in short axis. (B) Images were processed by manual delineation of the right ventricle (RV) and masking
of the left ventricle (LV). (C) The RV walls were defined as anterior, lateral and inferior and subsequently analyzed.
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patients progressively deteriorate until death ensues. The
cause of RV dysfunction in these patients has not been
clearly established, and its detection relies on indirect
methods limited to invasive hemodynamic measurements or
exercise tolerance. This study shows that ischemia is asso-
ciated with the presence of RV dysfunction.
Myocardial scintigraphy. Radiotracers such as 210Tl and
99mTc sestamibi have a myocardial distribution proportional
to coronary blood flow. Right ventricular visualization has a
direct correlation with systolic pulmonary arterial pressure
(27). Chronic pressure overload, as occurs in patients with
PPH, generates compensatory RV wall hypertrophy and an
Figure 2. (A) Short-axis projection of a myocardial single photon emission computed tomography (SPECT) with 99mTc-sestamibi, where right ventricular
(RV) wall hypertrophy and cavity dilation that increases after stress are evident. The left ventricle (LV) is shown without perfusion defects. (B) Myocardial
SPECT with 99mTc sestamibi processed to mask the LV enhances RV visualization where there are no evident perfusion defects. (C) Short-axis projection
of a myocardial SPECT with 99mTc sestamibi corresponding to D. (D) Myocardial SPECT with 99mTc sestamibi processed to enhance RV visualization,
where perfusion defects are evident in the basal third of the inferior and lateral walls of the RV in the stress images only (arrows). There is marked dilation
and hypertrophy of the RV walls.
Table 1. Hemodynamic and Echocardiographic Parameters of Patients With PPH
Category
No Ischemia
(14 Patients)
Ischemia
(9 Patients) p Value
Heart rate (3 min) 80 81 NS
Right atrial pressure (mm Hg) 4.8 (3, 7.5) 8 (7.05, 12.85) 0.037*
RV systolic pressure (mm Hg) 95.4 90 NS
RVEDP (mm Hg) 6.95 (4, 10.7) 12.6 (11, 20) 0.001*
MPAP (mm Hg) 64 56 NS
Cardiac index 2.5 2.14 NS
Venous O2 saturation (%) 65 (59, 65) 48 (40, 56) 0.0001*
Arterial O2 saturation (%) 92.6 88.6 NS
PaCO2 (mm Hg) 27 26.9 NS
PASP (mm Hg) 80.5 95 NS
LVEF (%) 63.5 62 NS
RV free wall width (cm) 0.878 1.01 NS
RV diastolic diameter (cm) 5.25 5.23 NS
*Statistically significant results. Results are expressed as medians, 25th and 75th percentiles and are added in parenthesis only if
the results were statistically significant.
LVEF 5 left ventricle ejection fraction; MPAP 5 mean pulmonary artery pressure; PaCO2 5 arterial carbon dioxide partial
pressure; PASP 5 pulmonary artery systolic pressure; RVEDP 5 right ventricle end-diastolic pressure.
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increase in coronary blood flow. This augments the uptake
of the radiotracer permitting a complete visualization of this
region of the heart. In our series, the median pulmonary
artery systolic pressure was 99.25 mm Hg, which permitted
an adequate observation of the RV perfusion in all of our
patients.
We observed myocardial uptake defects in nine patients
using SPECT. These findings suggest that there is a point
in the natural history of PPH when some patients develop
RV ischemia that may be detected by myocardial scintigra-
phy. It is conceivable that the alteration in RV perfusion
modifies the relaxation capacity of the heart, which may be
manifested as an elevation of the RVEDP (6.95 mm Hg
[group 1] vs. 12.6 mm Hg [group 2] [p , 0.001]).
However, the converse may also be true: elevation of the
RVEDP produces RV ischemia. Further impairment of RV
function will progressively elevate the RAP as shown in our
data (4.8 mm Hg [group 1] vs. 8 mm Hg [group 2] [p ,
0.037]) and may be manifested clinically by a worsening
NYHA classification. This hemodynamic pattern of RAP
$5 mm Hg (odds ratio [OR]: 8.75, confidence interval
[CI]: 95% 1.24 to 61) and RVEDP $9 mm Hg (OR: 12.83
[CI: 95% 1.69 to 97]) may be used to predict the presence
of RV ischemia.
Postulated origin of ischemia. Hypoxemia or myocardial
hypertrophy cannot explain the cause of RVEDP elevation,
because no differences were noted in the groups observed.
The possibility that cardiac ischemia resulting from coro-
nary artery disease leads to an increase in the RVEDP exists.
Major coronary artery anomalies were excluded by the
presence of a normal coronary angiography, but do not
discard anomalies in the RV microcirculation. Chronic
pressure overload generates myocardial wall hypertrophy in
order to overcome the systolic pressure in the outgoing
vessel. In the presence of severe RV systolic hypertension,
transmural and coronary perfusion pressures increase ac-
cordingly. This phenomenon limits RV coronary blood flow
to diastole only. Compensatory epicardial arterial enlarge-
ment occurs but is not proportional to wall hypertrophy (28)
nor is it observed at a capillary level (29), making the muscle
fibers more susceptible to ischemia. In animal models,
Murray and Vanter (30) have demonstrated that the sub-
endocardial to subepicardial blood flow ratio is diminished
at rest and after the injection of adenosine. This generates a
loss of coronary reserve due to an increase in the basal blood
flow, making the RV more susceptible to ischemia.
Although subendocardial ischemia secondary to wall
hypertrophy may not be the principal cause, we cannot
exclude its possible role, because the hypertrophied heart
increases its metabolic demands and ventricular dilation
increases wall stress (Law of Laplace). Other studies are
needed to clarify the mechanism responsible for the pro-
duction of RV ischemia.
Decrease in mixed venous oxygen saturation. The de-
crease in the mixed venous oxygen saturation may reflect a
low cardiac output found in the patients with ischemia.
Cardiac output was measured by thermodilution allowing
erroneous determinations intrinsic to the method and sec-
ondary to severe tricuspid regurgitation. Resting oxygen
uptake was determined at a time different from the right
heart catheterization, permitting differences in the results
obtained in oxygen uptake and other hemodynamic mea-
surements. Thus, it may be possible that the mixed venous
oxygen saturation was the only measurement that detected a
low cardiac output.
Conclusions. The presence of RV perfusion abnormalities
in patients with severe PPH can be identified by myocardial
scintigraphy. A direct correlation exists between the pres-
ence of images suggestive of RV ischemia obtained by
myocardial scintigraphy and RV dysfunction in patients
with PPH. Right ventricular ischemia is a factor associated
with RV dysfunction in patients with this disease.
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